EMA grants approval to initiate first-in-human Ph 1 trial with CS014
“The approval of the CTA for CS014 by EMA is a key milestone for Cereno. After five years of dedicated hard work from our team to evaluate and document the preclinical safety and efficacy of this candidate drug we will now proceed to initiate the first-in-human Phase I trial, evaluating the safety of CS014 in healthy volunteers. This marks the beginning of the next phase in the Company’s growth journey, as we now will be advancing two clinical-stage candidates for patients with rare and common cardiovascular diseases”, said Sten R. Sörensen, CEO, Cereno Scientific.
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
